共 50 条
Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression
被引:35
|作者:
Peters, Lars
[1
]
Mocroft, Anianda
[2
]
Soriano, Vincent
[3
]
Rockstroh, Juergen K.
[4
]
Losso, Marcelo
[5
]
Valerio, Laure
[6
]
Aldins, Pauls
[7
]
Reiss, Peter
[8
]
Ledergerber, Bruno
[9
]
Lundgren, Jens D.
[10
,11
]
机构:
[1] Univ Copenhagen, Fac Hlth Sci, Copenhagen HIV Programme, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] UCL, Sch Med, Res Dept Infect & Populat Hlth, London W1N 8AA, England
[3] Hosp Carlos III, Madrid, Spain
[4] Univ Bonn, Dept Internal Med, D-5300 Bonn, Germany
[5] Hosp JM Ramos Mejia, Buenos Aires, DF, Argentina
[6] CHU Nice, Hop Archet 1, Nice, France
[7] Infectol Ctr Latvia, Riga, Latvia
[8] Univ Amsterdam, Acad Med Bij, Amsterdam, Netherlands
[9] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
[10] Rigshosp, Div Infect Dis, Ctr Viral Dis KMA, DK-2100 Copenhagen, Denmark
[11] Rigshosp, Hosp Epidemiol, Ctr Viral Dis KMA, DK-2100 Copenhagen, Denmark
关键词:
antiretroviral therapy;
CD4;
hepatitis;
HIV;
viral load;
HIV-INFECTED PATIENTS;
ANTIRETROVIRAL THERAPY;
FIBROSIS PROGRESSION;
INDIVIDUALS;
DISEASE;
IMPACT;
D O I:
10.1097/QAI.0b013e318198a0e1
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background: Conflicting data exist whether hepatitis C virus (HCV) affects the CD4 cell recovery in patients with HIV starting antiretroviral treatment. Objective: To investigate the influence of HCV coinfection on the CD4 recovery in patients with maximum virologic suppression within the EuroSIDA cohort. Methods: Patients tested for anti-HCV antibodies and with at least 2 consecutive HIV viral loads (VLs) <50 copies per milliliter after starting combination antiretroviral therapy were eligible for inclusion. For each pair of VL <50 copies per milliliter, the annual change in CD4 count was calculated and compared between (1) HCV-seronegative vs. HCV-seropositive patients, (2) HCV genotypes 1-4 in HCV-RNA+ patients, and (3) viremic vs. aviremic (HCV-RNA < 615 IU/mL) in HCV-seropositive patients. Results were adjusted for known confounders. Results: Four thousand two hundred eight patients were included, representing 39,474 pairs of HIV VL measurements with VL <50 copies per milliliter and 12,492 person-years of follow-tip. The unadjusted annual change in CD4 count for HCV-seropositive and HCV-seronegative patients was 35.5 cells per milliliter (95% confidence interval 27.2 to 43.9) and 38.3 cells per milliliter (95% confidence interval 34.8 to 41.9), respectively. After adjustment, there was no difference in CD4 change when comparing, according to HCV serostatus (P = 0.17), between genotypes (P = 0.23) or when comparing HCV viremic vs. aviremic patients (P = 0.57). Adjusting additionally for HCV treatment and HCV-RNA VL did not change the findings. Conclusions: HCV serostatus did not influence the CD4 recovery in patients with HIV with maximum virologic suppression after starting combination antiretroviral therapy. Furthermore, no difference in CD4 gain was found when comparing distinct HCV genotypes in HCV-RNA+ patients or when comparing HCV viremic vs. aviremic HCV-seropositive patients.
引用
收藏
页码:457 / 463
页数:7
相关论文